Therapeutics: c-jun N-terminal kinase 2 (JNK2; MAPK9); JNK3 (MAPK10)

Neurology

INDICATION: Neurology

In vitro studies have identified aminopyrazole-based JNK2/3-selective inhibitors that could

Read the full 113 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE